Efficacy, Safety, and Determination of ABBV-383, a BCMA Bispecific Antibody, in Patients with RRMM

Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody, in patients with RRMMПодробнее

Updated safety and efficacy results of Abbv-383, a novel BsAb, in patients with R/R multiple myelomaПодробнее

How can the unique structure of the bispecific ABBV-383 impact its safety and efficacy?Подробнее

Phase I study of ABBV-383, a BCMA×CD3 bispecific antibody, in R/R myelomaПодробнее

Safety and efficacy of elranatamab in RRMM & prior BCMA therapies: Analysis from MagnetisMM studiesПодробнее

Updated phase 1 results of teclistamab, a BCMA × CD3 bispecific antibody, in RRMMПодробнее

Updated Safety and Efficacy Results of Abbv-383 | Ravi Vij, MD, MBA | ASH 2023Подробнее

First-in-Human Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Pts w/RRMMПодробнее

ASH23: Abbv-383 BCMA x CD3 Bispecific Antibody for Relapsed/Refractory Myeloma | Ravi Vij, MD, MBAПодробнее

AbbVie 383 - Guest LectureПодробнее

Bispecific antibody therapies for myeloma at ASH 2020Подробнее

Updated data: Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibodyПодробнее

Teclistamab: BCMA x CD3 bispecific antibody in RRMMПодробнее

Phase I study of ABBV383, a novel BCMAxCD3 bispecific antibody, in R/R multiple myelomaПодробнее

Safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatambПодробнее

Evaluating the safety and efficacy of elranatamab in multiple myelomaПодробнее

REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 1st-in-Human Study in RRMM PtsПодробнее

ABBV-383 - Upcoming Myeloma TreatmentПодробнее

Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 ResultsПодробнее